Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura
- PMID: 23993262
- DOI: 10.1016/j.amjmed.2013.03.021
Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura
Abstract
Background: Despite the widespread availability of plasmapheresis as a therapy, thrombotic thrombocytopenic purpura is associated with significant morbidity and mortality. There is a paucity of data on the predictors of poor clinical outcome in this population. Acute myocardial infarction is a recognized complication of thrombotic thrombocytopenic purpura. Little is known about the magnitude of this problem, its risk factors, and its influence on mortality in patients hospitalized with thrombotic thrombocytopenic purpura.
Methods: We used the 2001-2010 Nationwide Inpatient Sample database to identify patients aged ≥18 years with the diagnosis of thrombotic thrombocytopenic purpura (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 446.6) who also received therapeutic plasmapheresis (ICD-9-CM code 99.71) during the hospitalization. Patients with acute myocardial infarction were identified using the Healthcare Cost and Utilization Project Clinical Classification Software code 100. Stepwise logistic regression was used to determine independent predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura patients.
Results: Among the 4032 patients (mean age 47.5 years, 67.7% women, and 36.9% white) with thrombotic thrombocytopenic purpura who also underwent plasmapheresis, in-hospital mortality was 11.1%. Independent predictors of increased in-hospital mortality were older age (odds ratio [OR] 1.03; 95% confidence interval [CI], 1.02-1.04; P <.001), acute myocardial infarction (OR 1.89; 95% CI, 1.24-2.88; P = .003), acute renal failure (OR 2.75; 95% CI, 2.11-3.58; P <.001), congestive heart failure (OR 1.66; 95% CI, 1.17-2.34; P = .004), acute cerebrovascular disease (OR 2.68; 95% CI, 1.87-3.85; P <.001), cancer (OR 2.49; 95% CI, 1.83-3.40; P <.001), and sepsis (OR 2.59; 95% CI, 1.88-3.59; P <.001). Independent predictors of acute myocardial infarction were older age (OR 1.03; 95% CI, 1.02-1.04; P <.001), smoking (OR 1.60; 95% CI, 1.14-2.24; P = .007), known coronary artery disease (OR 2.59; 95% CI, 1.76-3.81; P <.001), and congestive heart failure (OR 2.40; 95% CI, 1.71-3.37; P <.001).
Conclusion: In this large national database, patients with thrombotic thrombocytopenic purpura had an in-hospital mortality rate of 11.1% and an acute myocardial infarction rate of 5.7%. Predictors of in-hospital mortality were older age, acute myocardial infarction, acute renal failure, congestive heart failure, acute cerebrovascular disease, cancer, and sepsis. Predictors of acute myocardial infarction were older age, smoking, known coronary artery disease, and congestive heart failure.
Keywords: Acute myocardial infarction; Mortality; Thrombotic thrombocytopenic purpura.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Cardiovascular Complications and Their Association With Mortality in Patients With Thrombotic Thrombocytopenic Purpura.Am J Med. 2021 Feb;134(2):e89-e97. doi: 10.1016/j.amjmed.2020.06.020. Epub 2020 Jul 18. Am J Med. 2021. PMID: 32687814
-
Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012.Transfusion. 2016 Jun;56(6):1451-8. doi: 10.1111/trf.13586. Epub 2016 Apr 15. Transfusion. 2016. PMID: 27079482 Free PMC article.
-
[Impact of gender on in-hospital death in hospitalized patients with acute myocardial infarction].Zhonghua Xin Xue Guan Bing Za Zhi. 2008 Jul;36(7):590-3. Zhonghua Xin Xue Guan Bing Za Zhi. 2008. PMID: 19100083 Chinese.
-
Myocardial infarction in thrombotic thrombocytopenic purpura: a single-center experience and literature review.Eur J Haematol. 2008 Oct;81(4):311-6. doi: 10.1111/j.1600-0609.2008.01112.x. Epub 2008 Jul 9. Eur J Haematol. 2008. PMID: 18616514 Review.
-
Thrombotic thrombocytopenic purpura as a rare complication in childhood systemic lupus erythematosus: case report and literature review.Hong Kong Med J. 2003 Oct;9(5):363-8. Hong Kong Med J. 2003. PMID: 14530532 Review.
Cited by
-
A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.Res Pract Thromb Haemost. 2024 Mar 19;8(3):102388. doi: 10.1016/j.rpth.2024.102388. eCollection 2024 Mar. Res Pract Thromb Haemost. 2024. PMID: 38651093 Free PMC article.
-
Cardiovascular Disease and Stroke in Immune TTP-Challenges and Opportunities.J Clin Med. 2023 Sep 14;12(18):5961. doi: 10.3390/jcm12185961. J Clin Med. 2023. PMID: 37762903 Free PMC article. Review.
-
How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?Ann Blood. 2023 Jun 30;8:11. doi: 10.21037/aob-21-87. Epub 2022 Apr 1. Ann Blood. 2023. PMID: 37200543 Free PMC article. No abstract available.
-
Impact of Acute Coronary Syndrome on Clinical Outcomes in Patients With Thrombotic Thrombocytopenic Purpura.Cureus. 2023 Mar 7;15(3):e35878. doi: 10.7759/cureus.35878. eCollection 2023 Mar. Cureus. 2023. PMID: 37033586 Free PMC article.
-
Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.J Clin Lab Anal. 2022 Jul;36(7):e24547. doi: 10.1002/jcla.24547. Epub 2022 Jun 11. J Clin Lab Anal. 2022. PMID: 35689538 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
